Verastem Inc (NASDAQ:VSTM) has been assigned a consensus rating of “Buy” from the ten ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $10.64.

Several analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Verastem in a research note on Wednesday, November 8th. Cann reissued a “buy” rating and issued a $15.00 target price (up from $6.00) on shares of Verastem in a research note on Sunday, December 10th. Oppenheimer reissued a “buy” rating and issued a $15.00 target price on shares of Verastem in a research note on Sunday, December 10th. Cantor Fitzgerald set a $17.00 price objective on Verastem and gave the company a “buy” rating in a research report on Sunday, December 10th. Finally, Roth Capital initiated coverage on Verastem in a research report on Friday, December 1st. They set a “buy” rating and a $12.00 price objective on the stock.

In other news, Director Timothy J. Barberich acquired 60,538 shares of the business’s stock in a transaction on Tuesday, December 5th. The shares were acquired at an average cost of $3.95 per share, with a total value of $239,125.10. Following the transaction, the director now owns 130,000 shares in the company, valued at approximately $513,500. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 6.51% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of VSTM. Cubist Systematic Strategies LLC bought a new stake in shares of Verastem in the 3rd quarter worth approximately $136,000. Northern Trust Corp boosted its position in shares of Verastem by 40.3% in the 2nd quarter. Northern Trust Corp now owns 73,750 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 21,178 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Verastem in the 3rd quarter worth approximately $195,000. OxFORD Asset Management LLP bought a new stake in shares of Verastem in the 2nd quarter worth approximately $234,000. Finally, Susquehanna International Group LLP boosted its position in shares of Verastem by 137.1% in the 3rd quarter. Susquehanna International Group LLP now owns 75,526 shares of the biopharmaceutical company’s stock worth $355,000 after purchasing an additional 43,675 shares in the last quarter. 28.66% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Verastem (NASDAQ:VSTM) opened at $3.05 on Tuesday. The company has a quick ratio of 3.12, a current ratio of 3.12 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $131.14, a PE ratio of -1.86 and a beta of 2.19. Verastem has a 12 month low of $1.11 and a 12 month high of $5.71.

Verastem (NASDAQ:VSTM) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.29). analysts predict that Verastem will post -1.74 EPS for the current fiscal year.

WARNING: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/16/verastem-inc-vstm-receives-average-rating-of-buy-from-brokerages-2.html.

About Verastem

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

Analyst Recommendations for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.